Literature DB >> 28675769

Outcomes of allogeneic stem cell transplantation in patients with paroxysmal nocturnal hemoglobinuria with or without aplastic anemia.

Sung-Eun Lee1, Sung Soo Park1, Young-Woo Jeon1, Jae-Ho Yoon1, Byung-Sik Cho1, Ki-Sung Eom1, Yoo-Jin Kim1, Seok Lee1, Chang-Ki Min1, Hee-Je Kim1, Seok-Goo Cho1, Dong-Wook Kim1, Woo-Sung Min1, Jong Wook Lee1.   

Abstract

OBJECTIVE: The aim of this study was to evaluate the long-term outcomes of allogeneic stem cell transplantation (SCT) in patients with paroxysmal nocturnal hemoglobinuria (PNH) with or without aplastic anemia (AA).
METHOD: A total of 33 patients with PNH clones who underwent allogeneic SCT were analyzed.
RESULTS: After a median follow-up of 57 months (range, 6.0-151.3), the 5-year estimated overall survival rate was 87.9±5.7%. Four patients died of transplant-related mortality (TRM). With the exception of one patient with early TRM, 32 patients were engrafted. Two patients who had developed delayed GF received a second transplant and recovered. The cumulative incidences of acute graft-vs-host disease (GVHD) (≥grade II) and chronic GVHD (≥moderate) were 27.3±7.9% and 18.7±7.0%, respectively. Twenty-one patients receiving SCT with reduced-intensity conditioning (RIC) had available follow-up data for PNH cell population for the first 6 months post-transplant. Analysis of these data revealed that the PNH clones disappeared within approximately 2 months.
CONCLUSION: RIC regimen was sufficient to eradicate PNH clones with sustained donor-type engraftment after allogeneic SCT. Therefore, application of allogeneic SCT with RIC should be considered in patients with PNH, in accordance with the severity of the underlying bone marrow failure.
© 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  allogeneic stem cell transplantation; aplastic anemia; paroxysmal nocturnal hemoglobinuria; reduced-intensity conditioning

Mesh:

Year:  2017        PMID: 28675769     DOI: 10.1111/ejh.12922

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  3 in total

1.  Development of hemolytic paroxysmal nocturnal hemoglobinuria without graft loss following hematopoietic stem cell transplantation for acquired aplastic anemia.

Authors:  Joseph H Oved; Natasha Stanley; Daria V Babushok; Yanping Huang; Jamie L Duke; Dimitrios S Monos; David T Teachey; Timothy S Olson
Journal:  Pediatr Transplant       Date:  2019-03-22

2.  Clinical observation of low-dose combination chemotherapy in refractory/recurrent paroxysmal nocturnal hemoglobinuria patients: A single-center retrospective analysis.

Authors:  Liyan Li; Hui Liu; Honglei Wang; Zhaoyun Liu; Yingying Chen; Chunyan Liu; Xiaoyu Zhao; Lijuan Li; Huaquan Wang; Zonghong Shao; Rong Fu
Journal:  J Clin Lab Anal       Date:  2022-01-14       Impact factor: 2.352

3.  Hematopoietic Stem Cell Transplantation for Patients with Paroxysmal Nocturnal Hemoglobinuria with or without Aplastic Anemia: A Multicenter Turkish Experience

Authors:  Fergün Yılmaz; Nur Soyer; Güldane Cengiz Seval; Sinem Civriz Bozdağ; Pervin Topcuoğlu; Ali Ünal; Leylagül Kaynar; Gökhan Özgür; Gülsan Sucak; Hakan Göker; Mustafa Velet; Hakan Özdoğu; Mehmet Yılmaz; Emin Kaya; Ozan Salim; Burak Deveci; İhsan Karadoğan; Güray Saydam; Fahri Şahin; Filiz Vural
Journal:  Turk J Haematol       Date:  2021-05-31       Impact factor: 1.831

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.